Pfizer stock a buy as company moves beyond COVID, Barron’s says

Pfizer’s two COVID blockbusters may decline over 60% in 2023 and the stock may have fallen out of favor, but now looks like the time to buy the shares, Andrew Bary writes in this week’s edition of Barron’s. Pfizer trades for 13 times projected 2023 earnings and yields 3.7%, more than double the S&P’s dividend rate. The payout, backed by ample earnings and one of the industry’s best balance sheets, looks very safe, the author notes. Reference Link